In Children's cancer group (CCG) 2891, newly diagnosed patients with AML were randomized between standard and intensive timing induction therapies. Patients in first remission who lacked an HLA matched family donor were randomized between an autologous bone marrow transplantation (ABMT) where marrow was purged with 4 hydroperoxycyclophosphamide and consolidation chemotherapy. One hundred and thirty seven patients received an ABMT. Myeloid and platelet engraftment occurred at a median of 44 and 42 days, respectively. Disease-free survival (DFS), relapse-free survival and overall survival at 8 years post induction were 47% (95% confidence interval (CI): 38-55), 50% (CI: 42-59) and 55% (CI: 46-63), respectively. Multivariate analysis of DFS showed WBC o50 000/ll and having received intensively timed induction therapy were associated with improved DFS. Recipients who received intensive timed induction therapy and whose WBC was less than 50 000/ll had a DFS at 8 years of 62% (CI: 49-73). Conversely, recipients who received intensive timed induction therapy patients whose WBC was X50 000/ll had a DFS of 33% (CI: 17-50), P ¼ 0.003. The results confirm previous studies that ABMT is effective post remission therapy for pediatric patients with AML in first remission.
Introduction
Bone marrow transplantation (BMT) is effective therapy for pediatric patients with AML in first remission. Since most patients lack a related histocompatible donor, autologous BMT (ABMT) has been used with success. [1] [2] [3] [4] [5] [6] [7] [8] Children's cancer group (CCG) 2891 was a phase III study to treat newly diagnosed children with AML. In that study, patients were randomized between intensive timed induction therapy and standard timed therapy. Patients who achieved remission status and who had an HLA identical or a single-locus mismatched, related donor were transplanted in first remission. Patients who lacked a related donor were randomized between high-dose cytosine arabinoside-based consolidation therapy and ABMT. We previously reported that overall survival (OS) and disease-free survival (DFS) were not significantly different between the chemotherapy and ABMT arms of CCG 2891 and that the use of intensive timing induction therapy was a significant factor in predicting favorable outcome. 1, 2 In that paper, results were presented based on the intent to treat model and lacked a detailed analysis of factors that may contribute to outcome. In this report, we present the further detailed results of the ABMT arm of CCG 2891 in terms of OS, relapse-free survival (RFS) and DFS.
Materials and methods

Patients
CCG 2891 was open from October 1989 to April 1995. The details of CCG 2891 have previously been reported. 1, 2 Eligibility criteria included newly diagnosed patients with AML. Patients with Down syndrome, AML as a second malignancy, granulocytic sarcoma who lacked marrow involvement, patients with acute promyelocytic leukemia (FAB M3) and patients with de novo myelodysplastic syndrome (MDS) were eligible for enrollment, but were not included in this analysis. Induction therapy consisted of a five-drug regimen containing dexamethasone, cytarabine, thioguanine, etoposide and rubidomycin (termed DCTER). Patients were randomized to receive intensive timing induction therapy vs standard timing therapy. In the standard timing arm, patients underwent a bone marrow examination 14 days after DCTER therapy. If the marrow showed clearing of leukemia, a second course of DCTER was given when counts recovered. If the day 14 marrow showed 440% blasts, a second course of DCTER was given at that time, regardless of counts. In the intensive timing arm, a second course of DCTER was given after a 6-day rest, regardless of counts. All patients received four courses of induction therapy. Patients who entered a complete remission (CR) (absolute neutrophil count (ANC) 41000/ml, platelet count4100 000/ml and o5% blasts seen in a recovering bone marrow aspiration) and who had an HLA matched sibling or a related donor disparate for one HLA locus were non-randomly assigned to receive an allogeneic BMT. Patients without a donor were randomized between an ABMT and consolidation chemotherapy.
Marrow harvesting and transplantation was performed at a CCG-approved BMT center. CCG-approved BMT centers perform a minimum of 20 transplants per year by a dedicated transplant team and have necessary supportive care facilities such as access to marrow processing, HLA typing and radiation therapy needed for BMT. Harvesting was recommended to be performed when the patient recovered from induction chemotherapy with an ANC 41000/ml and platelet count 4100 000/ml. The protocol allowed up to 12 weeks after completion of induction therapy to undergo marrow harvesting. The protocol recommended that at least 6 Â 10 8 nucleated cells/kg be harvested, which allowed for a back up graft containing 1 Â 10 8 nucleated cells/kg and the remainder of cells available for purging. The protocol accepted a minimum of 3 Â 10 8 nucleated cells/kg for purging. Marrow was harvested and purged with 4 hydroperoxycyclophosphamide (4-HC) at a concentration of 100 mg/ml as described previously. 9 Purged cells were cryopreserved in 10% DMSO in 50-100 ml aliquots using a programmable controlled rate freezer at a rate of 11C/min to a temperature of À701C and cryopreserved in the liquid phase of liquid nitrogen.
Conditioning
It was recommended that patients begin their preparative therapy within 2 weeks of harvesting. Conditioning consisted of 4 days of busulfan (4 mg/kg/day) given orally in four divided doses followed by 4 days of cyclophosphamide (50 mg/kg/day). Following a day of rest, autologous cells were infused. Post transplant supportive care was according to institutional guidelines. The protocol recommended trimethoprim/sulfamethoxasole and nystatin or clotrimazole be given until the ANC exceeded 1000/ml. Cytokines were not routinely used post transplant. Acyclovir was recommended for prophylaxis against recurrent herpes simplex stomatitis in seropositive patients.
Engraftment was defined as the third consecutive day the ANC exceeded 500/ml. Platelet engraftment was the defined as the third day the platelet count exceeded 20 000/ml without platelet transfusion. Toxicity was graded using the National Cancer Institute (NCI) toxicity scale.
Statistical analysis
Analyses are restricted to patients who underwent ABMT and include data obtained through January 14, 2004 . DFS was defined for those patients in a CR as the time from the end of induction to relapse or death; RFS was defined for patients in remission as the time from the end of induction to relapse or death due primarily to disease progression, censoring deaths primarily due to other causes. Patients lost to follow-up were censored at their last known point of study, with a cutoff of July 14, 2003. Survival estimates were calculated according to the method reported by Kaplan and Meier. 10 Corresponding confidence intervals (CIs) were calculated using Greenwood's formula. 11 Univariate analyses of prognostic factors were examined with respect to OS, RFS and DFS using a non-mixture parametric cure model (PCM). 12 This approach was employed because the primary interest was in assessing the prognostic significance of factors on the cure rate, that is, long-term survival estimate. A PCM fits these data well because there are few late events resulting in plateaus in which survival estimates are constant. The cured-fraction represented by such a plateau can be modeled explicitly with a PCM through the specification of a model for the cured-fraction and a continuous cumulative distribution function called the kernel. The effects of factors on the cure-fraction can be tested while accounting for factors affecting survival time via the kernel with shape and scale parameters. Herein, the logistic cure fraction and the logistic kernel were employed. All factors were considered using previously defined discrete categories. Factors significant in univariate analysis at Po0.05 for OS, RFS or DFS were considered for inclusion in a multivariate (multifactor) non-mixture PCM. All factors were included in each of the cure-fraction, shape and scale parameterizations.
Potential prognostic factors considered in the analyses for OS, RFS and DFS included demographic factors, gender, age and race. In addition, the following clinical characteristics at diagnosis were considered: WBC, hemoglobin level, platelet count, splenomegaly (palpable below the umbilicus), hepatomegaly (palpable below the umbilicus), presence of extramedullary disease, central nervous system (CNS) leukemia (defined as spinal fluid that contained 45 cells/ml with blasts seen on cytologic examination), cytochemical profile, FAB classification, presence of Auer rods, a history of MDS and the presence of cytogenetic abnormalities. In addition, the percent of bone marrow blasts and the peripheral blood ANC on day 7 of induction therapy were considered.
Results
One hundred and seventy-seven patients in remission on the end of induction therapy were randomized to receive an ABMT of which 137 actually received an ABMT. Of the 38 patients who did not receive ABMT, one patient underwent allogeneic BMT, six received chemotherapy, 11 suffered early relapse and 22 had unknown therapy. Ten patients who were not randomized to ABMT received an ABMT including eight patients who declined randomization, one randomized to chemotherapy and one randomized to allogeneic BMT. A total of 137 patients with de novo AML in CR1 underwent ABMT and are the focus of this report. Patient characteristics are shown in Table 1 . We examined the effect of induction timing on the number of marrow cells harvested. Recipients of standard timing had a median of 5.7 Â 10 8 nucleated cells/kg harvested compared to 5.2 Â 10 8 nucleated cells/kg in recipients of intensive timing therapy. These differences were not statistically significant (P ¼ 0.39). Induction therapy did not affect the time from the end of induction therapy to marrow harvesting. Recipients of standard timing therapy were harvested a median of 70 days after induction compared to 67 days seen in recipients of intensive timing therapy (P ¼ 0.55).
Engraftment and toxicity
The median time for the ANC to exceed 500/ml was 44 (range: 1-120) days. The median day for the platelet count to reach 20 000/ml without transfusion support was 42 (range: 0-131) days. Veno-occlusive disease (VOD) was noted in 11% (16 of 140) of patients. Grade 3 or 4 nonhematologic toxicities that occurred in more than 5% of cases included mucositis (n ¼ 16, 11.9%), hyperbilirubinemia (n ¼ 10, 7.5%), elevated hepatic transaminases (n ¼ 7, 5.2%), diarrhea (n ¼ 7, 5.2%) and nausea and vomiting (n ¼ 10, 7.5%). We examined whether the type of induction therapy received affected engraftment, VOD and treatment-related mortality and found that times for neutrophil, platelet and erythrocyte engraftment were not statistically different between recipients of standard and intensive timing induction therapy (data not shown). Recipients of intensive timing therapy had a 15.3% incidence of transplant-related mortality compared to a 7.4% incidence seen in recipients of standard timing therapy, but these differences were not statistically significant (P ¼ 0.3). Patients who received intensive timing therapy had a 13.6% incidence of VOD compared to 9.7% seen in recipients of standard timing therapy. These differences were not statistically different (P ¼ 0.5). Grade 3 or 4 neurotoxicity (which included seizures) was reported in three cases.
OS, RFS and DFS
OS, RFS and DFS at 8 years were 55% (CI: 46-63), 50% (CI: 42-59) and 47% (CI: 38-55), respectively. Sixty-two patients died. Relapse accounted for 55% of the deaths. The remainder of deaths was due to infection (18%), bleeding (5%), toxicity (6%) and other causes (16%). The median time to relapse was 188 days (range: 40 days to 2.9 years). Sixtythree patients had an isolated marrow relapse and two patients had concurrent marrow and CNS relapses.
Univariate analysis
Univariate analysis was performed to identify factors associated with outcome ( 
Multivariate analysis
Factors identified to be significant univariately (induction timing, age and WBC) were considered in multivariate analysis. Multivariate analysis indicated that induction timing is independently associated with OS (P ¼ 0.067), RFS (P ¼ 0.050) and DFS (P ¼ 0.046). WBC was also determined to be independently associated with RFS (P ¼ 0.005) and DFS (P ¼ 0.004). After adjusting for the other factors, age was no longer prognostic for OS (P ¼ 0.413), RFS (P ¼ 0.084) or DFS (P ¼ 0.187). The best outcome occurred in patients with WBC o50 000/ml who received intensive timing (8 years OS: 63%, RFS: 66%, DFS: 62%) ( Table 3 and Figure 1 ). Conversely, patients with WBC 450 000/ml who received standard timing had the worst outcome (8 years OS: 36%, RFS: 18%, DFS: 14%).
Outcome of early vs late relapses
There were 63 patients who relapsed post transplant at a median of 188 days (range: 40 days to 2.9 years). Of these, 37 patients received intensive timing induction, 25 patients Table 2 Univariate Kaplan-Meier estimates of OS, RFS and DFS at 8 years Abbreviations: CI ¼ confidence interval; DFS ¼ disease-free survival; OS ¼ overall survival; RFS ¼ relapse-free survival; WBC ¼ white blood cell. (Figure 2 ). This relationship is similar for those receiving intensive or standard induction timing.
Discussion
CCG 2891 represents the largest cohort of pediatric patients with AML who received ABMT as consolidation therapy in first remission. In 2891, patients received either standard or intensive timed induction therapy. Patients who lacked a matched sibling donor were further randomized between chemotherapy and ABMT. This report provides the detailed experience for patients undergoing ABMT. Among ABMT patients, 21% of the deaths were primarily due to infection. This is likely due to delayed engraftment associated with 4-HC purging. A potential contributing factor may be that cytokines were not used post-ABMT to minimize the duration of neutropenia. OS, RFS and DFS calculated from the end of induction were 55, 50 and 47% at 8 years, for patients who received the ABMT arm, respectively. For reference, recipients of chemotherapy had an OS, RFS and DFS at 8 years of 55, 46 and 44%, respectively. In addition, as previously reported, recipients of intensive timing induction therapy had a better DFS after ABMT than recipients of standard timing therapy. 1, 2 This study confirms our prior reports that recipients of intensive timing induction have superior outcomes and shows that a low WBC at diagnosis and having received intensive timing induction therapy were independent prognostic factors associated with improved RFS and DFS. Patients with an initial WBC o50 000/ml represented 74% of cases of pediatric AML 42 years. The observation that patients 0-2 years had a poor outcome may be explained by the fact that children o6 years old have increased clearance of oral busulfan resulting in a lower area under the curve. 13, 14 These results were reported after the inception of this study.
CCG 2891 was open between 1989 and 1995. Over the last decade, a number of advances have been made that could improve the outcomes and reduce the complications of ABMT. Preparative therapies can be modified to minimize the risk of relapse, especially for patients o2 years of age. It is possible to use intravenous busulfan or optimize the dose of oral busulfan based on pharmacokinetics. 15 Encouraging results of ABMT in children with AML in CR1 have been reported using total body irradiation (TBI) and melphalan. Bonetti et al. 5 reported 68% 5 years DFS in 53 children with AML in CR1 (45 of whom received mafosfamide purged grafts) who underwent ABMT following a preparative therapy of TBI and melphalan. Randomized trials comparing TBI to busulfan in adults have shown conflicting results. [16] [17] [18] [19] The superiority of TBI over busulfan is controversial and has not been carefully studied in pediatric AML. While TBI may eliminate the problems associated with busulfan clearance in children, this advantage may be offset by a potentially higher incidence of late effects in patients 0-2 years. 20 When 2891 opened, the role of purging was not considered. The role of purging in AML remains controversial. While gene marking studies 21 and retrospective analyses 22 support the role of purging in AML, purging needs to be evaluated in a prospective study. Although purging may contribute to improved RFS, this benefit may be offset by complications associated with prolonged neutropenia seen in this trial.
ABMT offers no survival advantage compared to consolidation chemotherapy [1] [2] [3] [4] and it is presently not being used in ongoing COG phase III studies for newly diagnosed patients with AML. In order for ABMT to be considered in future studies, new approaches are needed to reduce the probability of relapse after ABMT. Preliminary results using IL-2, 23-24 thalidomide 25 or anti-CD33 immunotoxins 26 are encouraging and need to be evaluated in prospective randomized clinical trials. We are encouraged that the use of newer anti-AML agents, together with the optimization of the preparative therapy and stratification of therapy based for younger patients may lead to improved outcomes for pediatric patients with AML undergoing ABMT, but whether results of ABMT would ever be superior to chemotherapy remains unknown.
